Parkinson's Clustering in Families of Non-Neuronopathic N370S GBA Mutation Carriers Indicates the Presence of Genetic Modifiers.


Journal

Journal of Parkinson's disease
ISSN: 1877-718X
Titre abrégé: J Parkinsons Dis
Pays: Netherlands
ID NLM: 101567362

Informations de publication

Date de publication:
2021
Historique:
pubmed: 23 2 2021
medline: 15 12 2021
entrez: 22 2 2021
Statut: ppublish

Résumé

Low penetrance of Parkinson's disease (PD) associated with GBA pathogenic variants indicates the presence of modifiers genes. Clusters of PD cases in certain families with GBA variants would serve as a strong evidence for the clinical relevance of such modifiers. We studied eight family trees of non-Parkinsonian, GBA-N370S homozygote, Gaucher probands, with multiple cases of PD. Differences in PD risk associated with different GBA variants were balanced by variant homozygosity. In these families, all PD cases stemmed from only one of the proband's parents. This observation provides a direct epidemiological evidence for genetic modifiers determining PD risk in GBA variant carriers.

Identifiants

pubmed: 33612495
pii: JPD202422
doi: 10.3233/JPD-202422
doi:

Substances chimiques

GBA protein, human EC 3.2.1.45
Glucosylceramidase EC 3.2.1.45

Types de publication

Letter

Langues

eng

Sous-ensembles de citation

IM

Pagination

615-618

Auteurs

Tama Dinur (T)

Gaucher unit, Shaare Zedek Medical Center, Jerusalem, Israel.

Michal Becker-Cohen (M)

Gaucher unit, Shaare Zedek Medical Center, Jerusalem, Israel.

Shoshana Revel-Vilk (S)

Gaucher unit, Shaare Zedek Medical Center, Jerusalem, Israel.
Faculty of Medicine, Hebrew University of Jerusalem, Israel.

Ari Zimran (A)

Gaucher unit, Shaare Zedek Medical Center, Jerusalem, Israel.
Faculty of Medicine, Hebrew University of Jerusalem, Israel.

David Arkadir (D)

Faculty of Medicine, Hebrew University of Jerusalem, Israel.
Department of Neurology, Hadassah Medical Center, Jerusalem, Israel.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH